2023
Objective Analysis and Clinical Significance of the Spatial Tumor-Infiltrating Lymphocyte Patterns in Non-Small Cell Lung Cancer.
Lopez De Rodas M, Wang Y, Peng G, Gu J, Mino-Kenudson M, Riess J, Velcheti V, Hellmann M, Gainor J, Zhao H, Schalper K. Objective Analysis and Clinical Significance of the Spatial Tumor-Infiltrating Lymphocyte Patterns in Non-Small Cell Lung Cancer. Clinical Cancer Research 2023, 30: 998-1008. PMID: 38127300, PMCID: PMC10922461, DOI: 10.1158/1078-0432.ccr-23-2457.Peer-Reviewed Original ResearchNon-small cell lung cancerTIL subsetsCell lung cancerImmune evasion mechanismsSubset of casesLymphocyte infiltration patternsPathology-based approachStrong biomarker potentialTIL markersNSCLC patientsImmunotherapy outcomesLymphocyte patternsLung cancerTumor bedWorse outcomesClinical significanceMost tumorsEvasion mechanismsStromal tissueTumor samplesMultiplexed immunofluorescenceBiomarker potentialTumorsInfiltration patternsImmunotherapy
2020
Compactness measures of tumor infiltrating lymphocytes in lung adenocarcinoma are associated with overall patient survival and immune scores
Ding R, Prasanna P, Corredor G, Lu C, Velu P, Le K, Leo P, Beig N, Velcheti V, Rimm D, Schalper K, Madabhushi A. Compactness measures of tumor infiltrating lymphocytes in lung adenocarcinoma are associated with overall patient survival and immune scores. 2020, 2. DOI: 10.1117/12.2549588.Peer-Reviewed Original Research
2017
Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
Gettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R, Wurtz A, Dong W, Cai G, Melnick MA, Du VY, Schlessinger J, Goldberg SB, Chiang A, Sanmamed MF, Melero I, Agorreta J, Montuenga LM, Lifton R, Ferrone S, Kavathas P, Rimm DL, Kaech SM, Schalper K, Herbst RS, Politi K. Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. Cancer Discovery 2017, 7: cd-17-0593. PMID: 29025772, PMCID: PMC5718941, DOI: 10.1158/2159-8290.cd-17-0593.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsPatient-derived xenograftsHLA class ILung cancerClass ICell surface HLA class ILung cancer mouse modelPD-1 blockadeStandard treatment algorithmCancer mouse modelLung cancer samplesDefective antigen processingCheckpoint inhibitorsPD-1Treatment algorithmMouse modelAntagonistic antibodiesDiverse malignanciesAntigen processingCancer samplesB2MHomozygous lossTumorsCancerRecurrent mutations
2016
Meta-analysis of tumor PD-L1 expression as a predictive biomarker of benefit from PD-1/PD-L1 axis inhibitors in solid tumors.
Khunger M, Rakshit S, Schalper K, Elson P, Pennell N, Stevenson J, Velcheti V. Meta-analysis of tumor PD-L1 expression as a predictive biomarker of benefit from PD-1/PD-L1 axis inhibitors in solid tumors. Journal Of Clinical Oncology 2016, 34: 11603-11603. DOI: 10.1200/jco.2016.34.15_suppl.11603.Peer-Reviewed Original Research
2013
Mutacin del gen KRAS en el cncer de colon y recto
Roa I, Snchez T, Majlis A, Schalper K. Mutacin del gen KRAS en el cncer de colon y recto. Revista Medica De Chile 2013, 141: 1166-1172. PMID: 24522420, DOI: 10.4067/s0034-98872013000900009.Peer-Reviewed Original ResearchConceptsKRAS mutationsPrimary tumorColorectal cancer tissue samplesTissue samplesColo-rectal cancerCancer tissue samplesColorectal cancerMetastatic tumorsTumor locationColorectal carcinogenesisG12C mutationCodon 13KRAS oncogeneCodon 12Tumor samplesTumorsExtraction sitesDirect sequencingCancerDistribution of mutationsMutationsPoint mutationsMetastasisRectumColonPin1 modulates ERα levels in breast cancer through inhibition of phosphorylation-dependent ubiquitination and degradation
Rajbhandari P, Schalper KA, Solodin NM, Ellison-Zelski SJ, Ping Lu K, Rimm DL, Alarid ET. Pin1 modulates ERα levels in breast cancer through inhibition of phosphorylation-dependent ubiquitination and degradation. Oncogene 2013, 33: 1438-1447. PMID: 23542176, PMCID: PMC3815749, DOI: 10.1038/onc.2013.78.Peer-Reviewed Original ResearchConceptsERα protein levelsERα proteinBreast cancerERα-positive breast cancerProtein levelsPotential surrogate markerRetrospective cohortSurrogate markerBreast carcinomaTherapy decisionsERα levelsESR1 levelsERα ubiquitinationCertain tumorsHuman tumorsDiscordant levelsESR1Pin1 levelsReceptor interactionUbiquitin-proteasome pathwayReceptor degradationImportant biomarkerTumorsCancerTransactivation function